A mono institutional retrospective analysis on the safety and efficacy of first-line Folfiri or Folfox (CT) plus bevacizumab (B) in young and elderly patients with metastatic colorectal cancer (MCC)

Autor:	D. Padalino, Enzo Maria Ruggeri, Fabrizio Nelli, Carlo Signorelli, F. Primi, M.G. Chilelli, G. D'Auria, Luca Moscetti, A. Fabbri, Isabella Sperduti, C. Blandino
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty Bevacizumab business.industry Colorectal cancer First line Hematology medicine.disease FOLFOX Internal medicine medicine FOLFIRI Retrospective analysis business medicine.drug
Zdroj:	ResearcherID
ISSN:	0923-7534
DOI:	10.1093/annonc/mdv340.51
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb2b60325dbff3ad3f062d57693175b7 https://doi.org/10.1093/annonc/mdv340.51 Zobrazit plný text záznamu